Trillium Therapeutics Inc (TRIL)

[NY1972]

SITC presentations:

CD47 is overexpressed on Merkel cell carcinoma and a target for SIRPaFc therapy

Lisa Johnson, PhD, Research Scientist - Trillium Therapeutics

Natalie Vandeven1, Natasja Nielsen Viller2, Alison O'Connor2, Hui Chen2, Bolette Bossen2, Eric Sievers2, Robert Uger2, Paul Nghiem1, Lisa Johnson2

1University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
2Trillium Therapeutics, Mississauga, ON, Canada

A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers

Sukhmani K. Padda, MD, Assistant Professor of Medicine - Stanford University School of Medicine

Combined blockade of CTLA-4 and CD47 with tumor irradiation extends survival in melanoma

Anthony L. Schwartz, PhD, Cancer Research Fellow - National Cancer Institute

Anthony L. Schwartz1, Pulak R. Nath1, Elizabeth Lessey-Morillon1, Lisa Ridnour2, David D. Roberts3

1National Cancer Institute, Bethesda, MD, USA
2National Cancer Institute, Frederick, MD, USA
3National Cancer Institute/Pathology, Bethesda, MD, USA